Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuroscience. Our team works collaboratively and relentlessly to advance our therapies with the goal of improving the lives of patients, their families, and their caregivers.
The Radius portfolio consists of commercial and clinical development assets that include mid to late-stage drug candidates.
In the area of bone health, we are dedicated to serving those patients suffering from bone loss like the 8.9 million osteoporotic fractures that occur annually worldwide1. In 2017, we launched our first commercial product in the U.S., TYMLOS® (abaloparatide injection), for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Abaloparatide-SC (subcutaneous injection) is being developed for the potential treatment of men with osteoporosis, and abaloparatide-TD (transdermal system) is being developed for the potential treatment of postmenopausal women with osteoporosis. In the fourth quarter of 2021 Radius announced topline results from both Phase 3 clinical trials.
The work of our Neuroscience group is centered around the clinical development of our investigational synthetic cannabidiol oral solution (RAD011), which has potential utilization in multiple orphan neurological disease areas. We are initially focused on the symptomatic treatment of two orphan neurodevelopmental disorders, Angelman syndrome (AS) and Prader-Willi syndrome (PWS). These disorders are diagnosed in as many as 16,000-27,0002 and 22,000-33,0003,4 people in the US, respectively. AS is genetic neurodevelopmental disorder characterized by profound developmental delay, seizures, intellectual disability, delayed or lack of communication, and ataxia. PWS is a complex genetic disorder with clinical manifestations on the endocrine and neurological systems, including debilitating hyperphagia and other behavioral symptoms. Our team is driven by the needs of those suffering from neurological diseases and seeks to expand its initiatives into other neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas in due course.
The Radius clinical pipeline includes the investigational drug elacestrant being developed for the potential treatment of patients with ER+ breast cancer. In July 2020, Radius entered into an exclusive global license agreement with Menarini Group for the development and commercialization of elacestrant, an investigative oral selective estrogen receptor degrader (SERD). In October 2021, the companies jointly announced positive topline results from the Phase 3 trial (EMERALD) evaluating elacestrant as a hormonal treatment for postmenopausal breast cancer.
1 Source: International Osteoporosis Foundation
2 Bird LM, “Angelman syndrome: review of clinical and molecular aspects” App Clin Genetics, 2014
3 Bohonowych et al., “The Global Prader–Willi Syndrome Registry” Genes, 2019. National Institute of Health, “Prader-Willi syndrome” Genetics Home Reference, 2014.
4 Verrotti et al., “Epilepsy in Prader-willi Syndrome: Clinical, Diagnostic and treatment aspects” World Journal of Pediatrics, 10(2), 108–113, 2014